CBIO's hemophilia B drug was awarded the title of orphan drug by FDA
-
Last Update: 2017-09-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Biovalley 2017-09-29 today, CBIO (catalyst Biosciences) announced that FDA awarded the company's CB 2679d / isu304 orphan drug for the treatment of hemophilia B CB 2679d / isu304 is a subcutaneous injection therapy of recombinant human coagulation factor IX variant Dr Nassim Usman, CEO of CBIO, said: "cb2679d / isu304 won the title of FDA orphan drug, which will promote the development of this promising B hemophilia therapy If our CB 2679d / isu304 therapy can finally be approved for marketing, it is undoubtedly a great good news for hemophilia patients whose vitality can only be declining " In June 2017, CBIO announced that the European Commission awarded CB 2679d / isu304 the title of orphan drug CBIO and its collaborator ISU abxis are working to assess the clinical trials of the drug in phase I / II in patients with severe B hemophilia The company expects to achieve transitional revenue by the end of this year and complete the full test results by the beginning of next year Hemophilia is a rare but serious bleeding disorder caused by a protein required for normal blood coagulation Hemophilia can be divided into three types: A, B and C the mutation of coagulation factor IX occurs in patients with B hemophilia CB 2679d / isu304, awarded the title of orphan drug by FDA, can receive a total of 4 years of subsidies, tax credits and exemptions of up to $2 million of FDA application fee each year, as well as seven years of exclusive drug sales rights.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
